Toxoplasmosis in the fetus and newborn: An update on prevalence, diagnosis and treatment

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 7, 2012, Pages 815-828

  Moncada, Pablo A ^a,b   Montoya, Jose G ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

congenital toxoplasmosis; fetal infection; folinic acid; incidence; newborn infection; prenatal screening; prevalence; prevention; pyrimethamine; spiramycin; sulfadiazine; Toxoplasma gondii; treatment

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; FOLINIC ACID; GAMMA INTERFERON; HLA DQ ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; MACROLIDE; PLACEBO; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE; SULFAMETHOXAZOLE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA;

AMNIOCENTESIS; BRADYZOITE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CONGENITAL DISORDER; CONGENITAL TOXOPLASMOSIS; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS DEATH; FETUS DISEASE; GESTATIONAL AGE; HUMAN; IMMUNE RESPONSE; INCIDENCE; INTRAUTERINE INFECTION; LABORATORY DIAGNOSIS; LIFE CYCLE; LISTERIOSIS; LYMPHOCYTIC CHORIOMENINGITIS; NEWBORN DISEASE; NEWBORN INFECTION; PARASITE VIRULENCE; PARVOVIRUS INFECTION; PLACENTAL TRANSFER; POLYMERASE CHAIN REACTION; PRENATAL SCREENING; PREVALENCE; REVIEW; RISK FACTOR; RUBELLA; SEROCONVERSION; SEROPREVALENCE; SYPHILIS; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT DURATION; VERTICAL TRANSMISSION;

ANTIBODIES, PROTOZOAN; DIAGNOSIS, DIFFERENTIAL; FEMALE; FETAL DISEASES; FETUS; HUMANS; INCIDENCE; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL DIAGNOSIS; SEROEPIDEMIOLOGIC STUDIES; TOXOPLASMA; TOXOPLASMOSIS, CONGENITAL;

EID: 84865794551     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.58     Document Type: Review

References (93)

1. Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin. Microbiol. Rev. 11(2), 267-299 (1998). (Pubitemid 28197354)
2. Montoya JG, Boothroyd JC, Kovacs JA. Toxoplasma gondii. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Churchill L (Ed.). Elsevier, PA, USA, 3495-3526 (2010).
3. Remington J, Mcleod R. Toxoplasmosis. In: Infectious Disease of the Fetus and Newborn Infant. Remington J, Klein JO, Wilson CB, Nizet V, Maldonado J (Eds). WB Elsevier Saunders Company, PA, USA, 918-1041 (2011). Considered to be the most authoritative review in the field of congenital toxoplasmosis. It provides historical context and detailed information on all aspects of the disease.
4. Remington JS, Cavanaugh EN. Isolation of the encysted form of Toxoplasma gondii from human skeletal muscle and brain. N. Engl. J. Med. 273(24), 1308-1310 (1965).
5. Carme B, Demar-Pierre M. [Toxoplasmosis in French Guiana. Atypical (neo-)tropical features of a cosmopolitan parasitosis]. Med. Trop. (Mars.) 66(5), 495-503 (2006). (Pubitemid 350214132)
6. Mercier A, Ajzenberg D, Devillard S et al. Human impact on genetic diversity of Toxoplasma gondii: Example of the anthropized environment from French Guiana. Infect. Genet. Evol. 11(6), 1378-1387 (2011). Analyzes the diversity of Toxoplasma gondii strains in French Guiana by comparing strains found in the wild areas of the country with those found in areas with high human activity.
7. Cenci-Goga BT, Rossitto PV, Sechi P, McCrindle CM, Cullor JS. Toxoplasma in animals, food, and humans: An old parasite of new concern. Foodborne Pathog. Dis. 8(7), 751-762 (2011).
8. Howe DK, Sibley LD. Toxoplasma gondii comprises three clonal lineages: Correlation of parasite genotype with human disease. J. Infect. Dis. 172(6), 1561-1566 (1995).
9. Ajzenberg D, Cogné N, Paris L et al. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. J. Infect. Dis. 186(5), 684-689 (2002). (Pubitemid 34925541)
10. Su C, Evans D, Cole RH, Kissinger JC, Ajioka JW, Sibley LD. Recent expansion of toxoplasma through enhanced oral transmission. Science 299(5605), 414-416 (2003). (Pubitemid 36120048)
11. Boyle JP, Rajasekar B, Saeij JP et al. Just one cross appears capable of dramatically altering the population biology of a eukaryotic pathogen like Toxoplasma gondii. Proc. Natl Acad. Sci. USA 103(27), 10514-10519 (2006). (Pubitemid 44051198)
12. Khan A, Dubey JP, Su C, Ajioka JW, Rosenthal BM, Sibley LD. Genetic analyses of atypical Toxoplasma gondii strains reveal a fourth clonal lineage in North America. Int. J. Parasitol. 41(6), 645-655 (2011).
13. Miller MA, Miller WA, Conrad PA et al. Type X Toxoplasma gondii in a wild mussel and terrestrial carnivores from coastal California: New linkages between terrestrial mammals, runoff and toxoplasmosis of sea otters. Int. J. Parasitol. 38(11), 1319-1328 (2008).
14. Sundar N, Cole RA, Thomas NJ, Majumdar D, Dubey JP, Su C. Genetic diversity among sea otter isolates of Toxoplasma gondii. Vet. Parasitol. 151(2-4), 125-132 (2008).
15. Peyron F, Lobry JR, Musset K et al. Serotyping of Toxoplasma gondii in chronically infected pregnant women: Predominance of type II in Europe and types I and III in Colombia (South America). Microbes Infect. 8(9-10), 2333-2340 (2006). (Pubitemid 44499053)
16. Sibley LD, Khan A, Ajioka JW, Rosenthal BM. Genetic diversity of Toxoplasma gondii in animals and humans. Philos. Trans. R Soc. Lond. B Biol. Sci. 364(1530), 2749-2761 (2009). Comments on the distribution of different genotypes and clones of the parasite across countries.
17. Gilbert RE, Freeman K, Lago EG et al.; European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl. Trop. Dis. 2(8), e277 (2008). Reports on the differences in prevalence and severity of congenital toxoplasmosis in infants born in Europe versus those born in Brazil. Ocular disease has a more aggressive clinical course in Brazil than in Europe.
18. Carme B, Bissuel F, Ajzenberg D et al. Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. J. Clin. Microbiol. 40(11), 4037-4044 (2002). (Pubitemid 35285786)
19. Demar M, Ajzenberg D, Maubon D et al. Fatal outbreak of human toxoplasmosis along the Maroni River: Epidemiological, clinical, and parasitological aspects. Clin. Infect. Dis. 45(7), e88-e95 (2007). (Pubitemid 47580397)
20. Suzuki Y, Wong SY, Grumet FC et al. Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J. Infect. Dis. 173(1), 265-268 (1996). (Pubitemid 26006832)
21. Mack DG, Johnson JJ, Roberts F et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int. J. Parasitol. 29(9), 1351-1358 (1999). (Pubitemid 29528124)
22. Jamieson SE, de Roubaix LA, Cortina- Borja M et al. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS ONE 3(6), e2285 (2008).
23. Jones JL, Dargelas V, Roberts J, Press C, Remington JS, Montoya JG. Risk factors for Toxoplasma gondii infection in the United States. Clin. Infect. Dis. 49(6), 878-884 (2009). Recent study that reports on the risk factors for the acquisition of Toxoplasma gondii infection in the USA.
24. Bowie WR, King AS, Werker DH et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet 350(9072), 173-177 (1997). (Pubitemid 27303624)
25. Vaudaux JD, Muccioli C, James ER et al. Identification of an atypical strain of Toxoplasma gondii as the cause of a waterborne outbreak of toxoplasmosis in Santa Isabel do Ivai, Brazil. J. Infect. Dis. 202(8), 1226-1233 (2010). Demonstrates that the parasite strain linked to a waterborne outbreak of toxoplasmosis in Brazil has a unique genetic structure.
26. López-Castillo CA, Díaz-Ramirez J, Gómez- Marín JE. [Risk factors for Toxoplasma gondii infection in pregnant women in Armenia, Colombia]. Rev. Salud Publica. (Bogota) 7(2), 180-190 (2005).
27. Boyer K, Hill D, Mui E et al.; Toxoplasmosis Study Group. Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin. Infect. Dis. 53(11), 1081-1089 (2011).
28. Boyer KM, Holfels E, Roizen N et al.; Toxoplasmosis Study Group. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am. J. Obstet. Gynecol. 192(2), 564-571 (2005). (Pubitemid 40214997)
29. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: Risk estimates for clinical counselling. Lancet 353(9167), 1829-1833 (1999). (Pubitemid 29251014)
30. Thiébaut R, Leproust S, Chêne G, Gilbert R; SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients' data. Lancet 369(9556), 115-122 (2007).
31. Hennequin C, Dureau P, N'Guyen L, Thulliez P, Gagelin B, Dufier JL. Congenital toxoplasmosis acquired from an immune woman. Pediatr. Infect. Dis. J. 16(1), 75-77 (1997). (Pubitemid 27063118)
32. Elbez-Rubinstein A, Ajzenberg D, Dardé ML et al. Congenital toxoplasmosis and reinfection during pregnancy: Case report, strain characterization, experimental model of reinfection, and review. J. Infect. Dis. 199(2), 280-285 (2009).
33. Azevedo KM, Setúbal S, Lopes VG, Camacho LA, Oliveira SA. Congenital toxoplasmosis transmitted by human immunodeficiency-virus infected women. Braz. J. Infect. Dis. 14(2), 186-189 (2010).
34. Lindsay DS, Dubey JP. Toxoplasma gondii: The changing paradigm of congenital toxoplasmosis. Parasitology 91-93 (2011).
35. Robert-Gangneux F, Murat JB, Fricker-Hidalgo H, Brenier-Pinchart MP, Gangneux JP, Pelloux H. The placenta: A main role in congenital toxoplasmosis? Trends Parasitol. 27(12), 530-536 (2011).
36. Wallon M, Franck J, Thulliez P et al. Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet. Gynecol. 115(4), 727-733 (2010). Provides the most up to date data on the sensitivity, specificity, negative predictive value and positive predictive value of amniotic fluid PCR for the prenatal diagnosis of congenital toxoplasmosis.
37. Delhaes L, Ajzenberg D, Sicot B et al. Severe congenital toxoplasmosis due to a Toxoplasma gondii strain with an atypical genotype: Case report and review. Prenat. Diagn. 30(9), 902-905 (2010).
38. Rosso F, Les JT, Agudelo A et al. Prevalence of infection with Toxoplasma gondii among pregnant women in Cali, Colombia, South America. Am. J. Trop. Med. Hyg. 78(3), 504-508 (2008). (Pubitemid 351845204)
39. Sobral CA, Amendoeira MR, Teva A, Patel BN, Klein CH. Seroprevalence of infection with Toxoplasma gondii in indigenous Brazilian populations. Am. J. Trop. Med. Hyg. 72(1), 37-41 (2005). (Pubitemid 41270306)
40. Lelong B, Rahelimino B, Candolfi E et al. [Prevalence of toxoplasmosis in a population of pregnant women in Antananarivo (Madagascar)]. Bull. Soc. Pathol. Exot. 88(1), 46-49 (1995).
41. Guerina NG, Hsu HW, Meissner HC et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N. Engl. J. Med. 330(26), 1858-1863 (1994). (Pubitemid 24188138)
42. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR Recomm. Rep. 49(RR-2), 59-68 (2000).
43. Roberts T, Frenkel JK. Estimating income losses and other preventable costs caused by congenital toxoplasmosis in people in the United States. J. Am. Vet. Med. Assoc. 196(2), 249-256 (1990).
44. Villena I, Ancelle T, Delmas C et al.; Toxosurv Network and National Reference Centre for Toxoplasmosis. Congenital toxoplasmosis in France in 2007: First results from a national surveillance system. Euro Surveill. 15(25), 19600 (2010). Reports on the incidence of congenital toxoplasmosis in France.
45. Varella IS, Canti IC, Santos BR et al. Prevalence of acute toxoplasmosis infection among 41,112 pregnant women and the mother-to-child transmission rate in a public hospital in South Brazil. Mem. Inst. Oswaldo Cruz 104(2), 383-388 (2009).
46. Gilbert R, Tan HK, Cliffe S, Guy E, Stanford M. Symptomatic toxoplasma infection due to congenital and postnatally acquired infection. Arch. Dis. Child. 91(6), 495-498 (2006). (Pubitemid 43836100)
47. Jankovic D, Kugler DG, Sher A. IL-10 production by CD4+ effector T cells: A mechanism for self-regulation. Mucosal Immunol. 3(3), 239-246 (2010).
48. Suzuki Y, Wang X, Jortner BS et al. Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells. Am. J. Pathol. 176(4), 1607-1613 (2010).
49. Suzuki Y, Sa Q, Gehman M, Ochiai E. Interferon-g- and perforin-mediated immune responses for resistance against Toxoplasma gondii in the brain. Expert Rev. Mol. Med. 13, e31 (2011).
50. Hunter CA, Lieberman LA, Mason N et al. Costimulation in resistance to infection and development of immune pathology: Lessons from toxoplasma. Immunol. Res. 27(2-3), 331-340 (2003).
51. Hunter CA, Remington JS. Immunopathogenesis of toxoplasmic encephalitis. J. Infect. Dis. 170(5), 1057-1067 (1994). (Pubitemid 24328603)
52. Melo MB, Kasperkovitz P, Cerny A et al. UNC93B1 mediates host resistance to infection with Toxoplasma gondii. PLoS Pathog. 6(8), e1001071 (2010).
53. Yarovinsky F, Hieny S, Sher A. Recognition of Toxoplasma gondii by TLR11 prevents parasite-induced immunopathology. J. Immunol. 181(12), 8478-8484 (2008).
54. Mendes EA, Caetano BC, Penido ML, Bruna-Romero O, Gazzinelli RT. MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes. Vaccine 29(27), 4476-4484 (2011).
55. Olariu TR, Remington JS, McLeod R, Alam A, Montoya JG. Severe congenital toxoplasmosis in the United States: Clinical and serologic findings in untreated infants. Pediatr. Infect. Dis. J. 30(12), 1056-1061 (2011). Reports the clinical and serological findings observed in untreated infants born with congenital toxoplasmosis in the USA. Although referral bias and genetics of the parasite might account for the higher frequency of disease severity observed in the USA, presence of prenatal serological screening and treatment in Europe, and its absence in the USA, might account for most of these transcontinental differences.
56. Vasconcelos-Santos DV, Machado Azevedo DO, Campos WR et al.; UFMG Congenital Toxoplasmosis Brazilian Group. Congenital toxoplasmosis in southeastern Brazil: Results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology 116(11), 2199.e1-2205.e1 (2009).
57. Gómez-Marin JE, de-la-Torre A, Angel-Muller E et al. First Colombian multicentric newborn screening for congenital toxoplasmosis. PLoS Negl. Trop. Dis. 5(5), e1195 (2011).
58. Desmonts G, Couvreur J. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N. Engl. J. Med. 290(20), 1110-1116 (1974).
59. Koppe JG, Rothova A. Congenital toxoplasmosis. A long-term follow-up of 20 years. Int. Ophthalmol. 13(6), 387-390 (1989). (Pubitemid 20098982)
60. Brown ED, Chau JK, Atashband S, Westerberg BD, Kozak FK. A systematic review of neonatal toxoplasmosis exposure and sensorineural hearing loss. Int. J. Pediatr. Otorhinolaryngol. 73(5), 707-711 (2009).
61. Peyron F, Garweg JG, Wallon M, Descloux E, Rolland M, Barth J. Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance. Pediatr. Infect. Dis. J. 30(7), 597-600 (2011).
62. Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet. Gynecol. 97(2), 296-300 (2001). (Pubitemid 32126349)
63. Thalib L, Gras L, Romand S et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. BJOG 112(5), 567-574 (2005). (Pubitemid 40675790)
64. Rabilloud M, Wallon M, Peyron F. In utero and at birth diagnosis of congenital toxoplasmosis: Use of likelihood ratios for clinical management. Pediatr. Infect. Dis. J. 29(5), 421-425 (2010).
65. Sterkers Y, Varlet-Marie E, Cassaing S et al. Multicentric comparative analytical performance study for molecular detection of low amounts of Toxoplasma gondii from simulated specimens. J. Clin. Microbiol. 48(9), 3216-3222 (2010). Demonstrates the importance of having a well-validated PCR method in each laboratory and the need for collaboration across laboratories rather than the 'perfect' DNA target for amplification.
66. Mandelbrot L, Jasseron C, Ekoukou D et al.; ANRS French Perinatal Cohort (EPF). Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort. Am. J. Obstet. Gynecol. 200(2), 160.e1-160.e9 (2009).
67. Naessens A, Jenum PA, Pollak A et al. Diagnosis of congenital toxoplasmosis in the neonatal period: A multicenter evaluation. J. Pediatr. 135(6), 714-719 (1999). (Pubitemid 30180420)
68. Wallon M, Cozon G, Ecochard R, Lewin P, Peyron F. Serological rebound in congenital toxoplasmosis: Long-term follow-up of 133 children. Eur. J. Pediatr. 160(9), 534-540 (2001). (Pubitemid 34208977)
69. Pinon JM, Dumon H, Chemla C et al. Strategy for diagnosis of congenital toxoplasmosis: Evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies. J. Clin. Microbiol. 39(6), 2267-2271 (2001). (Pubitemid 32531492)
70. Sterkers Y, Ribot J, Albaba S, Issert E, Bastien P, Pratlong F. Diagnosis of congenital toxoplasmosis by polymerase chain reaction on neonatal peripheral blood. Diagn. Microbiol. Infect. Dis. 71(2), 174-176 (2011).
71. Fuentes I, Rodriguez M, Domingo CJ, del Castillo F, Juncosa T, Alvar J. Urine sample used for congenital toxoplasmosis diagnosis by PCR. J. Clin. Microbiol. 34(10), 2368-2371 (1996). (Pubitemid 26307773)
72. Alford CA Jr, Stagno S, Reynolds DW. Congenital toxoplasmosis: Clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease. Bull. NY Acad. Med. 50(2), 160-181 (1974).
73. Boyer KM, Marcinak JF, Mcleod R. Toxoplasma gondii (Toxoplasmosis).In: Principles and Practice of Pediatric Infectious Disease. Long SS (Ed.). Elsevier Saunders Company, PA, USA (2009).
74. Erenberg A, Lemons J, Sia C, Trunkel D, Ziring P. Newborn and infant hearing loss: Detection and intervention. American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998-1999. Pediatrics 103(2), 527-530 (1999).
75. Harlor AD Jr, Bower C; Committee on Practice and Ambulatory Medicine; Section on Otolaryngology-Head and Neck Surgery. Hearing assessment in infants and children: Recommendations beyond neonatal screening. Pediatrics 124(4), 1252-1263 (2009).
76. Foulon W, Pinon JM, Stray-Pedersen B et al. Prenatal diagnosis of congenital toxoplasmosis: A multicenter evaluation of different diagnostic parameters. Am. J. Obstet. Gynecol. 181(4), 843-847 (1999). (Pubitemid 29503601)
77. Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin. Infect. Dis. 47(4), 554-566 (2008).
78. Hohlfeld P, Daffos F, Thulliez P et al. Fetal toxoplasmosis: Outcome of pregnancy and infant follow-up after in utero treatment. J. Pediatr. 115(5 Pt 1), 765-769 (1989). (Pubitemid 19270273)
79. Petersen E. Prevention and treatment of congenital toxoplasmosis. Expert Rev. Anti. Infect. Ther. 5(2), 285-293 (2007). (Pubitemid 46690956)
80. Gilbert R. Treatment for congenital toxoplasmosis: Finding out what works. Mem. Inst. Oswaldo Cruz 104(2), 305-311 (2009).
81. Cortina-Borja M, Tan HK, Wallon M et al.; European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: An observational prospective cohort study. PLoS Med. 7(10), e1000351 (2010). These data are highly suggestive that prenatal treatment reduces the incidence of severe neurological sequelae and death due to congenital toxoplasmosis.
82. Gilbert R, Gras L; European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 110(2), 112-120 (2003). (Pubitemid 36263105)
83. Desmonts G, Couvreur J. [Congenital toxoplasmosis. Prospective study of the outcome of pregnancy in 542 women with toxoplasmosis acquired during pregnancy]. Ann. Pediatr. (Paris) 31(10), 805-809 (1984). (Pubitemid 15176495)
84. Forestier F, Daffos F, Hohlfeld P, Lynch L. [Infectious fetal diseases. Prevention, prenatal diagnosis, practical measures]. Presse Med. 20(30), 1448-1454 (1991).
85. Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J. Antimicrob. Chemother. 22(Suppl. B), 193-200 (1988).
86. Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with a polymerasechain- reaction test on amniotic fluid. N. Engl. J. Med. 331(11), 695-699 (1994).
87. Thulliez P. Commentary: Efficacy of prenatal treatment for toxoplasmosis: A possibility that cannot be ruled out. Int. J. Epidemiol. 30(6), 1315-1316 (2001). (Pubitemid 34134281)
88. Valentini P, Annunziata ML, Angelone DF et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. Eur. J. Clin. Microbiol. Infect. Dis. 28(3), 297-300 (2009).
89. Béraud G, Pierre-François S, Foltzer A et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: An observational cohort study during 1994-2006. Am. J. Trop. Med. Hyg. 80(4), 583-587 (2009).
90. Soheilian M, Sadoughi MM, Ghajarnia M et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 112(11), 1876-1882 (2005).
91. Derouin F, Jacqz-Aigrain E, Thulliez P, Couvreur J, Leport C. Cotrimoxazole for prenatal treatment of congenital toxoplasmosis? Parasitol. Today (Regul. Ed.) 16(6), 254-256 (2000). (Pubitemid 30332130)
92. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital toxoplasma infection. Pediatrics 66(5), 767-774 (1980). (Pubitemid 11250438)
93. McAuley J, Boyer KM, Patel D et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin. Infect. Dis. 18(1), 38-72 (1994). (Pubitemid 24025917)